Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Share Insight on the New Data of Neural Sleeve for Neurological & other Disorders

In an interview with PharmaShots, Jeremiah Robison, Founder, and CEO at Cionic shared his views on the data of the Neural Sleeve gait study for patients with cerebral palsy, MS, stroke, and other neurological disorders Shots: Cionic has reported the results from the Neural Sleeve gait study which was conducted in the San Francisco Bay Area. The study showed an…

BySenior EditorDecember 27, 2021

EXCLUSIVE

Exclusive Interview with PharmaShots: Dr. Briggs W. Morrison of Syndax Share Insight on the Syndax’ Agreement with Incyte for Axatilimab

In an interview with PharmaShots, Dr. Briggs W. Morrison, MD, Chief Executive Officer and Director at Syndax share his views on the license agreement for axatilimab with Incyte to treat cGVHD and other fibrotic diseases Shots: The companies collaborated to develop and commercialize Syndax's axatilimab (anti-CSF-1R mAb) & will get a 50:50 US profit share Incyte will lead the…

BySenior EditorNovember 1, 2021

TOP 20

Top 20 Generics Pharma Companies Based On 2020 Revenue

Shots: Generic medicines are the backbone of the healthcare system and are identical to the innovator medicine in strength- effect- dosage form- and route of administration. These are allowed for sale after the patent expiry of the original drugs Our team at PharmaShots has compiled a list of the top 20 generic companies based on…

ByPrince GiriOctober 28, 2021

EXCLUSIVE

Exclusive Interview with PharmaShots: Jonathan Benjamin of Atreca Share Insight on the Data of ATRC-101 to Treat Solid Tumor

In an interview with PharmaShots, Jonathan Benjamin, MD, Ph.D., Senior Vice President & Clinical Research of Atreca shared his views on the initial data from the dose-escalation portion of its ongoing P-Ib trial for ATRC-101 to treat solid tumor Shots: The ongoing P-Ib trial evaluates ATRC-101 in patients with solid tumors & 26 patients had been dosed in a trial as of data cut-off…

BySenior EditorOctober 22, 2021

EXCLUSIVE

Exclusive Interview with PharmaShots: Kevin Cammack and Mark Warren Share Insight on Lyumjev U-100 Approved for Use in Insulin Pumps

In an interview with PharmaShots, Kevin Cammack, Head of Connected Care, Eli Lilly, and Mark Warren, MD, Director of Endocrine Clinical Trials and Laboratory Services, Physicians East share their views on the US FDAs approval of rapid-acting insulin, Lyumjev (insulin lispro-aabc injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2…

BySenior EditorOctober 4, 2021

Announcements

PharmaShots Celebrates Successful Accomplishment of Three Years

Shots: PharmaShots has started its journey in July 2018 as a concise, real-time news delivery platform and is proud to announce the completion of three years, with many more to come. Till now, PharmaShots has published 5,000+ posts with 10000+ subscribers With the completion of three years journey, PharmaShots is proud to announce the PharmaShots App to…

BySenior EditorJuly 25, 2021

EVENTS

12th Summit on Biosimilars & Innovator Biologics

June 22 ' 23, 2021 (EDT) | Virtual Conference The American Conference Institute invites you to attend the Virtual 12th Summit on Biosimilars & Innovator Biologics on June 22-23, 2021! Gain government and industry insights on the Innovator and Biosimilars Marketplace from the U.S. FTC, U.S. FDA, USPTO, and leading In-House Counsel. As the number…

BySenior EditorApril 30, 2021

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2021

The first quarter of 2021 highlights new approvals, M&A, and the clinical data of COVID-19 vaccines. The companies expand their working in COVID-19 by targeting South African & Brazil variants along with other emerging variants Starting with the latest acquisition, Amgen acquired Five Prime for $1.9B, Jazz acquired JW while Boston acquired Preventice. This quarter…

ByRidhi RastogiApril 4, 2021

THOUGHTSPOT

Wearables in the Market & their Roles

Wearables are electronic devices consisting of sensors that can receive data of user's personal health and exercise schedules. They work wirelessly or with the help of other devices such as smartphones, tablets, or laptops. The market of wearable technology was valued at $15.74 billion in 2015 & expected to extend $51.60 billion by 2022 at…

ByParshuram NivruttiFebruary 9, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2020

The fourth quarter of 2020 contains multiple initiations of clinical trials, big approvals, and numerous deals. COVID-19 related news remains at the peak in this quarter Multiple companies received regulatory bodies EUA for their vaccines and treatments for COVID-19. Initiating with, Regeneron sought the US FDA's EUA for REGN-COV2 Ab combination while Health Canada accelerated…

ByDipanshu DixitJanuary 14, 2021

Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Share Insight on the New Data of Neural Sleeve for Neurological & other Disorders

Exclusive Interview with PharmaShots: Dr. Briggs W. Morrison of Syndax Share Insight on the Syndax’ Agreement with Incyte for Axatilimab

Top 20 Generics Pharma Companies Based On 2020 Revenue

Exclusive Interview with PharmaShots: Jonathan Benjamin of Atreca Share Insight on the Data of ATRC-101 to Treat Solid Tumor

Exclusive Interview with PharmaShots: Kevin Cammack and Mark Warren Share Insight on Lyumjev U-100 Approved for Use in Insulin Pumps

PharmaShots Celebrates Successful Accomplishment of Three Years

12th Summit on Biosimilars & Innovator Biologics

PharmaShots’ Key Highlights of First Quarter 2021

Wearables in the Market & their Roles

PharmaShots’ Key Highlights of Fourth Quarter 2020

Contact US

FOLLOW US